Investment analysts at Ladenburg Thalmann increased their target price on shares of Questcor Pharmaceuticals (NASDAQ: QCOR) from $49.00 to $50.00 in a note issued to investors on Monday.

The analysts wrote, “In our opinion, there are three important disclosures in the 8K which increase our confidence in our bullish stand on QCOR. These include: 1) QCOR purchased 800,000 shares of its common stock (average price $36.31); 2) paid prescriptions in nephrotic syndrome (NS) reached record levels (90-95 paid prescriptions) in March 2012; and 3) timing for sales force expansions in Nephrology and Neurology have accelerated by 2 months and 3 months, respectively.”

Questcor Pharmaceuticals traded up 2.87% on Monday, hitting $41.27. Questcor Pharmaceuticals has a 52-week low of $18.21 and a 52-week high of $45.95. The company has a market cap of $2.624 billion and a price-to-earnings ratio of 33.16.

The company last announced its quarterly results on Wednesday, February 22nd. It reported $0.47 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.41 EPS by $0.06. The company’s quarterly revenue was up 157.7% on a year-over-year basis. Analysts expect that Questcor Pharmaceuticals will post $0.55 EPS next quarter.

A number of other analysts have also recently weighed in on QCOR. Analysts at Zacks downgraded shares of Questcor Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Tuesday, February 7th. Separately, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Questcor Pharmaceuticals in a research note to investors on Friday, February 3rd. Finally, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Questcor Pharmaceuticals in a research note to investors on Tuesday, January 17th.

Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. Questcor primary product is H.

Stay on top of analysts' coverage with our daily email newsletter that provides a concise list of analysts' upgrades, downgrades and price target changes for each day. Click here to register.

...